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A B S T R A C T
A preclinical porcine model that reliably predicts human food eﬀect of fenoﬁbrate was developed. Fenoﬁbrate
was administered to pigs as model compound with a positive food eﬀect. Two diﬀerent types of fed conditions
were explored: a FDA style breakfast and a standard pig pellet feed. In order to assess if complete stomach
emptying had been achieved under the employed fasting protocol, the amount of gastric and intestinal content
was evaluated post-mortem. In addition, the protocol was designed to evaluate gastric emptying in the pre- and
postprandial state using paracetamol as a marker. The study conﬁrmed that micronized fenoﬁbrate displayed a
positive food eﬀect with a similar fold diﬀerence to humans in FDA style fed state. Post-mortem assessment of
stomach and intestinal content conﬁrmed signiﬁcantly lower content in the fasted compared to the pig pellet fed
state. In the case of paracetamol, a delayed gastric emptying in the fed state was not observed, which may
suggest that the Magenstrasse phenomena reported in humans, may also occur in landrace pigs. The study
demonstrated the utility of a food eﬀect protocol in landrace pigs as a pre-clinical approach to predict human
food eﬀects and provided new insights into gastric emptying in pigs.
1. Introduction
Food dependent oral bioavailability of drugs can have a signiﬁcant
impact on patient treatment, hence there are clear clinical advantages
to predicting food dependent bioavailability early in the drug devel-
opment process. Recent observations indicate that over 40% of new
medicines licensed since 2010 display variable food eﬀects (O'Shea
et al., 2018). In preclinical development, it is crucial to predict the
impact of food on oral pharmacokinetics as early as possible in drug
development, so as to allow optimisation of formulation design to mi-
grate the risk of variable food eﬀect bioavailability and avoid costly
reformulation later in the product lifecycle (Fleisher et al., 1999,
Koziolek et al., 2019). While there is a range of in vitro approaches to
predict food eﬀects, which have been reviewed recently (Pentafragka
et al., 2018), current regulatory guidance mandate food eﬀect studies in
humans, which are time and resource intensive. In addition, with the
increasing drive to ensure clinical studies in humans are conﬁrmatory,
rather than exploratory (Selen et al., 2014), there is a need for pre-
clinical models to assess the interplay between formulation and food for
a given drug candidate and its impact on drug levels in vivo.
Food intake can result in large variability of oral absorption by al-
tering the physiological and physicochemical conditions in the gastro-
intestinal (GI) tract, including (a) slower gastric emptying inﬂuencing
cmax and tmax, (b) increased gastric pH, altering the solubility of ioni-
sable compounds, (c) increase of gastrointestinal ﬂuid volume, which
changes the volume available for solubilisation/dissolution, (d) in-
creased secretion of bile, cholesterol, phospholipids etc. resulting in
increased solubilisation for poorly soluble drugs. Therefore, the phy-
siological diﬀerences in the postprandial state eﬀects drug solubilisa-
tion and absorption depending on the drug and formulation char-
acteristics (Abuhelwa et al., 2017; Custodio et al., 2008; Gu et al., 2007;
Lentz, 2008; Varum et al., 2013).
Thus, the FDA provided guidelines on how to design clinical trials
for new drug products, recommending dosing in both fasted and fed
states in order to investigate food eﬀects under standardised conditions.
The FDA guidance deﬁnes that a food-eﬀect is established if the 90%
conﬁdence intervals for the ratio of population geometric means, based
on log-transformed data, for either AUC0→∞ or cmax fall outside the
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80–125% bioequivalence limits (FDA, 2002). The standardised fed state
conditions are represented by a high fat FDA breakfast, containing
800–1000 kcal, with approximately 150, 250, and 500–600 calories
from protein, carbohydrate and fat, respectively (FDA, 2002). While
this regulatory guidance establishes clearly the conditions for in-
vestigating the impact of food in a clinical setting, protocols for asses-
sing food eﬀects in preclinical models are less clearly deﬁned, albeit it is
expected that fed state conditions should generally match the standard
FDA style fed state conditions.
The canine model is the most commonly preclinical model used for
assessing food eﬀects. Lentz et al. (2007) developed a protocol in a
canine model for predicting food eﬀects in humans. While in some cases
dogs tended to overestimate food eﬀects, in particular when 100 g of
FDA breakfast were administered, the model was useful for the iden-
tiﬁcation of both positive and negative food eﬀects of nine drugs using a
50 g FDA breakfast (Lentz et al., 2007). Over the last decade, the pig has
become an increasingly popular preclinical model in regulatory tox-
icology and pharmacokinetics due to the similarities in gastrointestinal
anatomy and physiology to humans (Bode et al., 2010; Henze et al.,
2018b; Puccinelli et al., 2011; Sjogren et al., 2014; Suenderhauf and
Parrott, 2013; Walters et al., 2011). While there are various breeds of
pigs used in pharmaceutical research, the domestic landrace pig and the
Göttingen minipig are the most commonly employed. In general, both
breeds are considered to be comparable to humans in terms of phy-
siological pH and intestinal physiology, as recently reviewed (Henze
et al. 2018b). Henze et al. (2018) recently reported that pigs compare
more favourably than dogs at predicting the extent of absolute bioa-
vailability in humans, albeit based on a limited set of 15 comparable
studies (Henze et al., 2018b). However, the rate of drug absorption in
pigs is tending to be slower than in humans, this most likely reﬂect a
prolonged and more variable gastric emptying in pigs. The variability in
estimates of gastric emptying in pigs has been reported to be inﬂuenced
by the fasting period and methods employed (Suenderhauf et al., 2014).
In many cases insuﬃcient fasting protocols may have resulted in an
incomplete stomach emptying of food prior to dosing. Therefore, there
is a need to deﬁne a standardised protocol that ensures complete sto-
mach emptying in the fasted state in food eﬀect studies.
Paracetamol has previously been used as a marker for gastric
emptying (Suenderhauf et al., 2014), as a BCS class I compound food is
not expected to have any impact on the extent of paracetamol bioa-
vailability, however food intake is anticipated to reduce the rate of
absorption due to a delay gastric emptying. Suenderhauf et al. (2014)
reported that gastric emptying rates in fasted Göttingen minipigs for
paracetamol were longer and more variable than estimated in humans.
Interestingly, post-mortem evaluation of the stomach contents revealed
that even after a 12 h fasting period, a signiﬁcant amount of food re-
mained in the stomach and therefore dosing conditions were not re-
ﬂective of the desired fasted conditions. Interestingly complete stomach
emptying was observed in pigs fed a liquid meal the day before dosing
or by pre-treating with metoclopramide, a pro-kinetic agent
(Suenderhauf et al., 2014). Henze et al. (2018), attempted to extend
these post-mortem observations to establishing a fasting/fed protocol in
Göttingen minipigs by administering metoclopramide intramuscularly
2 h before oral dosing of paracetamol. However, the pre-treatment of
metoclopramide did not appear to regulate gastric emptying under the
fed and fasted conditions (Henze et al., 2018a).
The current study was designed with the objective of assessing the
utility of landrace pigs to predict food eﬀects, using the model drug
fenoﬁbrate, a BCS class II drug with a known positive food eﬀect in
humans. Two diﬀerent fed state conditions were explored: ﬁrstly, a FDA
style breakfast consisting of a high fat, high caloric meal and secondly,
a standard pig pellet feed. An additional objective of the present study
was to investigate the eﬃciency of the employed fasting protocol, as to
date most of the studies observed as a cofounding factor that pigs may
have not been dosed in a truly fasted state. Therefore, the gastro-
intestinal contents of pigs were evaluated post-mortem after the
employed fasting regime and the pig standard feed. Additionally, pigs
were co-administered paracetamol to evaluate if diﬀerences in gastric
emptying between fasted and fed states resulted in changes in para-
cetamol absorption in vivo.
2. Materials and methods
2.1. Materials
Paracetamol, 2-acetamidophenol and fenoﬁbric acid were pur-
chased from Sigma-Aldrich (Ireland) Ltd. Fenoﬁbrate was purchased
from Kemprotec Ltd. (UK). Hard gelatine capsules (Size 0) were ob-
tained from Capsugel (Coni-Snap®). Lipantil™ Micro 67mg hard cap-
sules and Paralief™ 500mg tablets were commercially sourced from
local pharmacies. All food components used in preparing FDA re-
commended breakfast were purchased commercially. All other chemi-
cals and solvents were of analytical grade or HPLC grade, respectively,
and were purchased from Sigma–Aldrich (Ireland) and used as received.
2.2. In vivo study
The study was carried out under the licence issued by the Health
Products Regulatory Authority (HPRA), Ireland, as directed by the
Cruelty to Animals Act, Ireland and EU Statutory Instruments (Licence
number AE19130/P058). Local University ethical committee approval
was obtained. Four male landrace pigs (16.8–18.7 kg, mean 17.96 kg)
were sourced locally and housed individually at the University’s
Biological Services Unit. Landrace pigs of this size were selected to get
as close to the size of Göttingen minipigs and beagle dogs used in
previously comparable studies (Lentz et al., 2007; Henze et al., 2018a).
Pigs were fed approximately 175 g of standard weanling pig pellet feed
twice daily. The ﬁnal feed of 175 g was given 24 h prior to dosing. As
part of the study design any remaining food was removed 16 h before
dosing, however, no food remained at this point in any of the groups.
The study was a non-randomised, one sequence, three-way crossover
design, where the pigs were dosed in the fed state (350 g pig weanling
food which was considered a normal or ‘standard’ feed for landrace pigs
of this size – equivalent to 20% protein, 6.5% oil, 3.5% ﬁbre or 987 kcal
in total) in week one, fasted on week 2, fed a half portion of a standard
high-caloric, high-fat FDA breakfast (444 kcal, 315 g, one slice of bacon,
one slice buttered toast, one fried egg, 118mL whole milk, 60 g hashed
brown potatoes) in week 3. The mass of FDA breakfast fed equated to
approximately 18–20 g/kg of body weight.
On day one, an indwelling intravenous catheter was inserted into
the jugular vein via an ear vein under general anaesthesia, as previously
described (Framstad and Aass, 2000; Pairis-Garcia et al., 2014; Swindle,
2010, 2016; Swindle and Smith, 2013). Following an overnight fast on
day three, oral formulations of 67mg fenoﬁbrate (Lipantil® Micro
67mg hard gelatine capsules) and 500mg of paracetamol tablets
(Paralief™) were administered simultaneously with the aid of a dosing
device, after which the pigs received 50mL of water via a syringe.
Under fed state conditions, pigs received the meal 30min prior to oral
dosing. After dosing, pigs were returned to their pens. Blood samples
(4 mL) were collected at time zero (pre-dosing) and 0.5, 1, 1.5, 2, 2.5, 3,
3.5, 4, 5, 6, 8, 10, 12 and 24 h post-dosing. Water was available ad
libitum throughout the study period and the animals were fed with
175 g of pig weanling pellet feed 8 h post-dose. All blood samples were
collected in heparinised tubes (Sarstedt, Germany) and immediately
centrifuged at 3220 g for 5min at 4 °C (Eppendorf 5810r swinging
bucket rotor centrifuge, Eppendorf AG, Hamburg, Germany). Plasma
was collected and stored at− 80 °C prior to analysis. A six-day washout
period was used between each phases. All animals remained in good
health throughout the study.
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2.3. Bioanalysis of paracetamol
The plasma concentrations of paracetamol were determined by a
reversed-phase HPLC. The Agilent 1200 series HPLC system comprised
a binary pump, variable wavelength detector, autosampler and column
oven. A Synergi, C18 reversed phase column (250×4.6mm, 4 μm)
(Phenomenex Inc., Macclesﬁeld, UK) was used for the chromatographic
separation. The mobile phase consisted of 0.1% (w/v) acetic acid:
methanol (70:30, v/v) and was used at a ﬂow rate of 1mL/min. The
detection wavelength was set at 254 nm. The retention time for para-
cetamol was approximately 6.5min and 11min for the internal stan-
dard (2-acetamidophenol). However, due to the presence of fenoﬁbric
acid, the main metabolite of fenoﬁbrate, in the same sample a wash run
was performed after every third sample. This was a 20-minute cleaning
run with a gradient from 70% acetic acid and 30% methanol to 20%
acetic acid and 80% methanol over ﬁve minutes. The system was held
at this composition for ﬁve minutes before returning to the original
gradient over ﬁve minutes and re-equilibrating the column at this
gradient for ﬁve minutes.
Paracetamol was extracted from the plasma samples by liquid–li-
quid extraction. 100 µL of plasma sample was transferred to an
Eppendorf microcentrifuge tube. 60mg sodium chloride, 10 µL internal
standard (250 µg/mL, 2-acetamidophenol) were added to the tube.
Sodium chloride was added to precipitate and denature protein before
extraction. The tubes were mixed using a benchtop vortex. 1000 µL of
ethyl acetate was added to extract paracetamol. The tubes were shaken
for 30 s using a vortex mixer followed by centrifugation at 11,500g for
9min (Hermle z233M-2 ﬁxed angle rotor centrifuge, HERMLE
Labortechnik GmbH, Wehingen, Germany) at ambient temperature.
The supernatant was transferred to a polypropylene vial and evapo-
rated to dryness under a stream of nitrogen at 60 °C. A second extrac-
tion step was carried out by adding 1000 µL ethyl acetate to the pre-
cipitate again, followed by 30 s vortexing and centrifuging under the
same conditions. The supernatant was transferred to the corresponding
round-bottom polypropylene vial from the previous step and evapo-
rated to dryness under a stream of nitrogen at 60 °C. The residue was
dissolved in 100 µL mobile phase and 20 µL was injected into the
column. The limit of quantiﬁcation by this procedure was 500 ng/mL
and the assay was linear between 500 ng/mL and 15,000 ng/mL. The
extraction eﬃciency was greater than 89% across the concentration
range.
2.4. Bioanalysis of fenoﬁbrate
The pharmacokinetic evaluation of fenoﬁbrate was based on the
quantiﬁcation of fenoﬁbric acid, as fenoﬁbrate is a prodrug and after
absorption fenoﬁbrate is rapidly hydrolysed to the major active meta-
bolite fenoﬁbric acid. Fenoﬁbric acid was analysed from the plasma
samples, using a validated HPLC-UV method, as previously described
(Griﬃn et al., 2014; O'Shea et al., 2015). Brieﬂy, 0.5 mL plasma was
spiked with 20 μL of a suldinac 100 μg/mL solution in methanol as an
internal standard. Proteins were precipitated through addition of
0.5 mL of 25% NaCl solution and 1mL of 1% H3PO4 in methanol with
thorough mixing. Samples were centrifuged at 11.500 g for 9min
(Hermle z233 M-2 ﬁxed angle rotor centrifuge; HERMLE Labortechnik
GmbH, Wehingen, Germany). The clear supernatants were injected
onto a Synergi Fusion C18 reversed phase column (250×4.6mm,
4 μm) (Phenomenex Inc., Macclesﬁeld, UK) using the same system as
described above for paracetamol. The mobile phase consisted of 80%
methanol and 20% water (adjusted to pH 2.5 with phosphoric acid) at a
ﬂow rate of 1mL/min, resulting in an elution of fenoﬁbric acid at
6.5 min. UV detection was performed at 286 nm. The analysis showed
linearity over the range of 50–2000 ng/mL with an LOQ of 50 ng/ml
and extraction recoveries were ≥95%.
2.5. Gastric and intestinal ﬂuid sample collection
For the post mortem assessment, 12 pigs were used – 4 pigs from the
current in vivo study and 8 pigs from other unrelated in vivo studies. All
pigs were euthanized humanely following completion of in vivo phar-
macokinetic experiments. All animals were euthanized by intravenous
injection of pentobarbital sodium followed by potassium chloride. The
peritoneal cavity was exposed by midline incision and the stomach and
small intestine were isolated. Occluding ligatures were applied to the
proximal cardiac sphincter and distal to the pyloric sphincter as well as
at the proximal and distal ends of the small intestine. Once both ends
were secured, both the stomach and small intestine were removed from
the peritoneal cavity. The luminal ﬂuid was collected in sterile 50mL
sample tube, pH was measured using a calibrated Jenway 3510 pH
meter and the samples were frozen until further analysis.
Thawed samples were homogenised using a T25 Ultra-Turrax®
homogeniser (IKA®-Werke GmbH & Co. KG, Germany) probe for 5min
at 200 rpm. Samples were centrifuged at 3220 g for 10min at ambient
temperature (Eppendorf 5810r swinging bucket rotor centrifuge,
Eppendorf AG, Hamburg, Germany) to separate solid content from li-
quid content. Liquid supernatant was macroscopically observed to be
free from solids and was removed and placed in 50mL sterile tubes.
Solid content was measured using lab balances, while the volume of
liquid content was measured in a graduated cylinder. The following
feeding regimens were evaluated:
(i) Fasted state: ﬁnal feed was given 24 h prior to euthanasia. As part
of the study design any remaining food was removed 16 h before
euthanasia.
(ii) Fed state: ﬁnal feed (350 g pig pellet feed), was given 2 h prior to
euthanasia.
2.6. Pharmacokinetic analysis
Exposure after oral administration was estimated by calculating the
area under the plasma concentration curve (AUC) for 8 h and 24 h post
dosing for fenoﬁbric acid and paracetamol by using PKPlus
(Gastroplus.9.5). The AUC 24h–∞ in the fasted state was calculated using
the mean elimination constant from the i.v. dataset (Griﬃn et al.,
2014). AUC and mean residence time (MRT) were determined from
non-compartmental analysis. The peak plasma concentrations (cmax)
and the time for their occurrence (tmax) were noted directly from the
individual plasma concentration versus time proﬁles. The absolute
bioavailability (Fa) of fenoﬁbrate and paracetamol was calculated ac-
cording to Eq. (1), using previously published intravenous data from
our group (Griﬃn et al., 2014; Henze et al., 2018a). All pharmacoki-
netic parameters are reported as mean ± SD.
⎜ ⎟⎜ ⎟= ⎛
⎝
⎞
⎠
∗ ⎛
⎝
⎞
⎠
F AUC
AUC
Dose
Dosea
oral
i v
i v
oral. .
. .
(1)
Mean absorption time (MAT) was calculated from intravenous and
oral MRT, according Eq. (2):
= +MRT MAT MRTpo iv (2)
Food eﬀect was calculated using the fold diﬀerence (FD) in the AUC
in fed vs the fasted state using Eq. (4):
⎜ ⎟= ⎛
⎝
⎞
⎠
FD
AUC
AUC
fed
fasted (3)
Fold diﬀerences (FD) are presented, where possible, as mean
FD ± standard error of the fold diﬀerence (SEFD) as calculated by Eq.
(5):
= × +SE FD
SE
AUC
SE
AUCFD
fed
fed
fasted
fasted
2
2
2
2 (4)
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where FD is the mean fold diﬀerence in food eﬀect, AUCfed and
AUCfasted are the represent the mean AUC in the fed and fasted states,
respectively, and SEfed and SEfasted represent the standard errors cor-
responding to these values, respectively.
2.7. Deconvolution
The correlation between absorption and plasma concentration was
previously described by Langenbucher et al. (1982). The oral admin-
istration can be treated as the response function R(t) and the weighting
function W(t) is based on the data after an intravenous bolus admin-
istration. The correlation of the weighting and response function de-
pends on the input and can be described according to Eq. (5):
∫= −R t I W t θ dθ( ) (ϑ) ( )t0 (5)
The principal of numerical deconvolution was previously described
by (Langenbucher, 1982):
=
− ∑ ∗= − +I x
R t T I x W x
W x
( )
[ ( )/ ( ) ( )]
( )i
k
n
k n k
i
1 1
(6)
I(Xi) combines the release and absorption process, T is the time
interval, (Xk) and W(Xk) the average input rate and weight between the
times Xk-1 and Xk. The method of numerical deconvolution was used to
have a dynamic illustration of the absorption process. Mean time points
for 25%, 50% and 75% absorption were calculated from the deconvo-
lution proﬁles, to present the totally absorbed fraction of the com-
pounds. The deconvolution was conducted in Excel, results are pre-
sented as means and their standard error mean (± S.E.M.).
2.8. Statistical analysis
After using the Bartlett’s test to check for equal variance, a one-way
ANOVA was used to determine the statistical signiﬁcance of calculated
in vivo bioavailability and Cmax. Tukey’s post hoc test was used to
identify pairwise statistical signiﬁcance. A nonparametric statistical test
was used, the Kruskal Wallis rank test, with Dunn’s multiple compar-
ison rank sums to determine the signiﬁcance in tmax. All statistical
analyses were performed using GraphPad Prism version 5, p-values
of< 0.05 were considered signiﬁcant.
3. Results
3.1. Eﬀect of food on oral pharmacokinetics of fenoﬁbrate in landrace pigs
The mean plasma concentration proﬁles obtained after oral ad-
ministration of Lipantil®Micro (67mg micronized fenoﬁbrate) to fasted
and fed pigs are presented in Fig. 1. The mean plasma proﬁles display a
similar ranking and trends as the individual plasma proﬁles for each
pig. Two diﬀerent feeding regimes were compared, a FDA style- high-
fat, high caloric breakfast and a standard pig pellet feed, which were
administered 30min prior to the oral dosing of fenoﬁbrate. The key
pharmacokinetic parameters for fenoﬁbric acid are summarised in
Table 1.
During the ﬁrst 8 h post dose (Fig. 1A), a marked diﬀerence in the
absorption proﬁle of fenoﬁbrate in fasted pigs versus pigs fed the FDA
style breakfast was observed. A clear positive food eﬀect was observed
for fenoﬁbrate following oral dosing after the FDA breakfast. The AUC
0-8h increased from 10.6 ± 2.9 μg⋅h/mL in the fasted state to
19.1 ± 3.8 μg⋅h/mL in the fed state, reﬂecting a statistically signiﬁcant
increase in bioavailability of 1.82 ± 0.18, (p < 0.05) (Fig. 2).
Pigs were allowed access to food 8 h post dosing, the food intake
correlated with a distinct second peak in plasma concentration proﬁles
at 10 h of the fasted study group. In pigs the secretion of bile acids has a
similar pattern to humans (Henze et al. 2018b.). Therefore, the inges-
tion of food 8 h post dosing, results in an increase of bile salts in the
intestine which leads to increased solubilisation capacity in the intes-
tine. This observation of a second peak is similar to previous ﬁndings
for Lipantil micro in fasted landrace pigs, most likely reﬂecting a post
prandial induced secondary absorption phase of drug that remained in
the gastrointestinal tract even 8–10 h post dosing (O'Shea et al., 2015).
As a result of this secondary absorption peak in plasma concentration, a
longer mean absorption time (MAT) (13.4 ± 8.1 h) and the time to
reach peak concentrations (tmax) (5.5 ± 4.4 h) were obtained in the
fasted study leg. Interestingly, the mean tmax found in fasted landrace
pigs was comparable to recently published human data of 8.6 ± 4.0 h
for a micronized fenoﬁbrate formulation (Hens et al., 2015). A distinct
secondary peak was not evident in the fed groups, suggesting that no
secondary absorption phase of fenoﬁbrate occurred in these pigs.
Fig. 1. (A) Plasma concentration proﬁles
after oral administration of 67mg fenoﬁ-
brate to landrace pigs 0–8h, (B) Plasma
concentration proﬁles after oral adminis-
tration of 67mg fenoﬁbrate to landrace pigs
over 24 h, 8 h post dosing animals were al-
lowed access to food; fasted state (●), FDA
breakfast (□), pig pellet feed (▲);
(mean ± SEM, n= 4).
Table 1
Pharmacokinetic parameters of fenoﬁbrate (fenoﬁbric acid) after oral admin-
istration of 67mg per animal (mean ± SD, n= 4).
Pharmacokinetic parameters
Fasted FEDFDAbreakfast FEDPigpellet
cmax (μg/mL) 2.24 ± 0.68 3.24 ± 0.59 2.91 ± 0.60
tmax (h)a 7.5 (2.5–12.0) 5.0 (4.0–8.0) 6.5 (2.5 ± 12.0)
AUC0→8h (μg⋅h/mL) 10.64 ± 2.90 19.14 ± 3.83c 18.85 ± 5.62
AUC0→24h (μg⋅h/mL) 28.19 ± 7.01 36.79 ± 2.52 38.88 ± 12.63
AUC0-∞ (μg⋅h/mL) 31.36 ± 7.45 41.98 ± 3.89 51.63 ± 21.06
Fa0-8h (%)b 21.61 ± 5.59 38.89 ± 7.55c 38.29 ± 11.42
Fa0-∞ (%)b 62.11 ± 14.75 83.13 ± 7.71 102.26 ± 41.71
Food eﬀect 0-8hd – 1.82 ± 0.18 1.94 ± 0.94
Food eﬀect 0-∞d – 1.39 ± 0.30 1.78 ± 0.96
MAT (h)b 13.42 ± 8.08 7.03 ± 3.25 10.73 ± 6.03
MRT p.o. (h) 19.22 ± 7.49 12.84 ± 1.45 16.54 ± 5.36
F0-∞=(AUC(oral)0-∞/AUC(iv)0-∞) * (Dose(iv)/Dose(oral).
F0-8h= (AUC(oral)0-8h/AUC(iv)0-∞) * (Dose(iv)/Dose(oral).
a Median (range).
b Absolute bioavailability and MAT was calculated with i.v. data previously
published from (Griﬃn et al., 2014).
c Signiﬁcant diﬀerence to the fasted equivalent parameter (p < 0.05).
d Calculated according to Eq. (4), reported as mean values of the individual
fed/fasted ratios.
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Additionally, over the full 0-∞ h period, given the secondary ab-
sorption phase in the fasted state, there was no signiﬁcant diﬀerence in
AUC0-∞ between both fed states and the fasted state. The individual
mean fold fed/fasted diﬀerence for the FDA style breakfast was de-
termined to be 1.39 ± 0.30, indicative of an overall positive food ef-
fect, however no longer statistically signiﬁcant over the 0-∞ h.
Interestingly this fold diﬀerence is comparable to the food eﬀect of
fenoﬁbrate reported in humans, of approximately 35–50% increase in
bioavailability in the fed state (Guivarc'h et al., 2004).
In pigs administered the pig pellet feed, a trend towards a faster
absorption was evident from the average plasma concentration proﬁle
(Fig. 1A), however plasma concentrations were more variable within
this study leg. As a result of this greater variability, diﬀerences in AUC
between fasted and pig pellet fed groups were not statistically sig-
niﬁcant.
3.2. Post mortem assessment of gastrointestinal contents in fasted and fed
state
Previous studies identiﬁed that Göttingen minipigs displayed an
incomplete stomach emptying, even after an overnight fasting period
(Suenderhauf et al., 2014). In order to assess if truly fasted state con-
ditions were achieved in landrace pigs after an overnight fast, post
mortem gastrointestinal content samples were collected. The fasted
gastrointestinal content was compared to a fed state, where pigs were
fed 350 g of a standard pig pellet feed in the morning 2 h pre eu-
thanasia.
Fig. 3 illustrates the content samples collected from the stomach and
the small intestine under fasted and fed conditions. On average the
amount of solid content remaining in the stomach of the fasted group
was 10.1 ± 6.4 g and a ﬂuid volume of 33.4 ± 10.7 mL. The low
overall amount of solid content in the stomach conﬁrms that the fasting
protocol in landrace pigs was suﬃcient to generate fasted state condi-
tions, resulting in near-complete emptying of solid content from the
stomach. In the case of the fed state group, a signiﬁcant higher solid
content of 112.9 ± 60.1 g and liquid volume of 95.1 ± 29.4 mL was
observed in the stomach.
In the small intestine, average ﬂuid volume in the fasted state was
111.4 ± 28.8 mL compared to a volume of 150.1 ± 39.3mL in the fed
state. Small intestine ﬂuid volume was not signiﬁcantly diﬀerent in pre
and post prandial conditions. On the other hand, the intestinal solid
content was signiﬁcantly diﬀerent between the fasted and the fed state
in the small intestine, with a solid content of 20.9 ± 18.5 g in the
fasted animals and 106.1 ± 29.5 g in the fed animals.
3.3. Absorption of paracetamol in pre- and post-prandial state
Previously, paracetamol has been used to provide an estimate of
gastric emptying (Christiansen et al., 2015; Henze et al., 2018a;
Suenderhauf et al., 2014). Thus, in order to further compare gastric
emptying in the current protocol for landrace pigs, paracetamol was co-
administered with fenoﬁbrate. Generally, the administration of a drug
with food should lead to a slower gastric emptying, resulting in a longer
tmax (Christiansen et al., 2015). Therefore, any diﬀerences in tmax and
absorption rate of paracetamol between fasted and fed conditions
should provide further insights into food inﬂuences on gastric emptying
(Christiansen et al., 2015).
Table 2 summarises the pharmacokinetic parameters after oral ad-
ministration of paracetamol (Paralief® 500mg tablets). Fig. 4A re-
presents the plasma concentration–time proﬁle of paracetamol in
landrace pigs in the fasted state, after a FDA breakfast and standard pig
pellet feed, respectively. No signiﬁcant diﬀerence was observed be-
tween the fasted state and the two feeding regimes. In the fasted state
tmax ranged from 2.5 h to 5.0 h, with a mean value of 3.5 ± 1,1h. These
estimates of paracetamol absorption rates in landrace pigs are com-
parable to values obtained in fasted minipigs, where Henze et al. re-
ported a mean of 4.2 ± 1.6 h (Henze et al., 2018a). The values were
also similar to the mean tmax of 3.5 h reported for a paracetamol capsule
in male minipigs, albeit slower than the mean tmax of 1.4 h reported for
a paracetamol tablet in the same study (Suenderhauf et al., 2014).
Comparing tmax in fasted and fed states, no signiﬁcant diﬀerences were
found (Fig. 4B) and critically, a delayed absorption of paracetamol in
the fed state was not evident. The reported mean data showed the same
ranking as the individual proﬁles.
This lack of diﬀerence between the fasted and the fed study legs
after oral administration of paracetamol was also reﬂected in the
comparable MAT (Fig. 4C) and the release proﬁle of paracetamol, cal-
culated by numerical deconvolution (Fig. 4D). The MAT of approxi-
mately 4 h of paracetamol was observed in fasted conditions, which was
similar to a previous study in minipigs (Henze et al., 2018a). While a
short MAT indicates a fast drug absorption, a longer MAT indicates a
delayed or prolonged absorption. A key limitation of a previous study in
minipigs was the high variability of MAT of paracetamol in both fed (%
CV=100.6) and fasted state (% CV=30.2), which limited the power
to detect diﬀerences in absorption between fasting and fed state con-
ditions (Henze et al., 2018a). In this study, absorption of paracetamol in
landrace pigs was more consistent as evidenced by lower variability in
MAT with % CV=19.8 for the fasted state and % CV=15.1 in the fed
state. Despite the lower overall variability within both treatment
groups, no signiﬁcant diﬀerences were observed between fasted and fed
state.
4. Discussion
4.1. Utility of landrace pigs to predict food eﬀects in humans
Bioavailability of fenoﬁbrate increased signiﬁcantly after the co-
administration with the FDA style breakfast, relative to the fasted state
during the 8 h post-dosing period (Fig. 2, Table 1). This study conﬁrms
that a standardised preclinical food-eﬀect protocol can be employed in
landrace pigs to predict the food-eﬀect of fenoﬁbrate in humans. This is
to the best of our knowledge the ﬁrst report in the literature, where a
food eﬀect was demonstrated in a pig model for a drug product with a
known positive food eﬀect in humans. Previously, Christiansen et al.
(2015) did not detect a signiﬁcant food eﬀect with the FDA breakfast in
minipigs for atazanavir (positive food eﬀect) and pravastatin (negative
food eﬀect) (Christiansen et al., 2015). A key diﬀerence of the current
study was to employ a higher caloric FDA breakfast (mean 19 g food/kg
bodyweight), which was approximately twice the amount of food
Fig. 2. Bioavailability after 8 h of 67mg fenoﬁbrate orally administered to
fasted pigs, pigs fed a FDA breakfast and pigs fed a standard pig pellet feed.
Absolute bioavailability was calculated with i.v. data previously published from
(Griﬃn et al., 2014); (mean ± SD, n= 4).
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compared to previous studies in minipigs (10 g/kg). By comparison to
the established canine food protocol, dogs receive 5 g/kg to mimic
human food eﬀects studies (Lentz et al., 2007). Therefore, the results
obtained in the present study suggests that the caloric content in the fed
state may need to be higher in pigs in order to mimic human food ef-
fects.
In humans, a∼ 35% bioavailability increase under fed conditions
for a micronized fenoﬁbrate formulation has been reported in product
labelling (FDA, 2017). Under fasted conditions fenoﬁbrate is poorly
absorbed because of the poor water solubility, the absorption in the fed
state increased due to higher concentrations of bile salts and lipid di-
gestion products (O'Shea et al., 2018). While a direct estimate of the
individual AUC fold diﬀerence from cross over studies in humans has
not been reported, Guivarc'h et al. (2004) reported the overall mean
AUC0-∞ fold diﬀerence in fed versus fasted as 1.39 ± 0.74 for a mi-
cronized formulation in 7 human volunteers (Guivarc'h et al., 2004).
This compares favourably to the mean AUC0-∞ fold diﬀerence under fed
versus fasted conditions in this pig study, which is calculated as
1.34 ± 0.34, as illustrated in Fig. 5.
Additionally, a second feeding regime using standard pellet pig feed
was included in the study to assess the suitability of the standard pig
feed to predict food eﬀect diﬀerences. Henze et al. (2018), previously
suggested that the standard pig feed may have advantages in terms of
less training and habituation to ingestion of the FDA style breakfast and
the porcine digestive system may simply be better adjusted to normal
pig food (Henze et al., 2018a). While in the current study the mean AUC
of fenoﬁbrate in the pig pellet group was higher with a trend of a po-
sitive food eﬀect, overall the data was very variable resulting in no
statistical signiﬁcant diﬀerence between the fasted and pig pellet fed
state. While pigs may be more familiar with a standard pig pellet feed as
a food source, clearly consistency of the standard pig pellet food (e.g.
rheological properties) will diﬀer substantially from the FDA style
breakfast. It may also be interesting to speculate whether the trend
towards a faster rate of absorption of fenoﬁbrate in pigs who received
the standard pig pellet food reﬂected a faster emptying of pig feed from
the stomach, leading to a triggering of bile secretion and subsequent
enhanced solubilisation and absorption of fenoﬁbrate. However overall,
it would therefore appear that using the standard pig pellet feed as a
food source in a protocol for food eﬀect studies is of limited merit in
matching FDA style post prandial conditions.
4.2. Assessing fasted state conditions in landrace pigs
In pigs gastric emptying has been reported to be more variable
which can lead to prolonged gastric lag times, relative to human esti-
mates. Even after an overnight fast, obtaining a truly fasted condition in
the stomach may not be achieved (Suenderhauf et al., 2014). One
reason can be that pigs have the ability to retain food for a long time
due to torus pyloricus, a protuberance at the pylorus of pigs (Henze
et al., 2018a). Using paracetamol as a marker of gastric emptying in the
current study the pharmacokinetics results demonstrate no signiﬁcant
Fig. 3. Post mortem assessment of ﬂuid volume and solid content of landrace pigs under fasted and fed conditions. I. fasted state: overnight fasting period; II. fed
state: pigs received standard pig pellet feed (350 g) 2 h before euthanasia. Plots show the median (solid line), Whiskers: min. to max. value, n=6.
Table 2
Pharmacokinetic parameters of paracetamol, oral administration 500mg per
animal (mean ± SD, n=4). No statistical diﬀerence was observed between
the study legs.
Pharmacokinetic parameters
Fasted FEDFDAbreakfast FEDPigpellet
cmax (μg/mL) 16.41 ± 5.48 11.88 ± 4.64 14.76 ± 2.46
tmax (h)a 3.25 (2.5–5.0) 3.75 (3.0–5.0) 3.75 (2.5–6.0)
AUC0→8h (μg⋅h/mL) 70.02 ± 20.70 61.32 ± 13.07 74.71 ± 11.04
AUC0→24h (μg⋅h/mL) 81.40 ± 24.41 70.47 ± 14.97 95.64 ± 17.16
MAT (h)b 3.89 ± 0.77 4.16 ± 0.63 4.77 ± 0.96
MRT p.o. (h) 5.70 ± 0.74 5.97 ± 0.20 6.58 ± 0.90
a Median (range).
b MAT was calculated with i.v. data previously published from (Henze et al.,
2018a).
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diﬀerence between the fasted and the fed state. The results are therefore
similar to previous observations in minipigs, however in the previous
study we could not discount that the lack of food eﬀect in paracetamol
could be masked by incomplete stomach emptying in the fasted state.
The current study in landrace pigs therefore addresses a potential
limitation of the previous work by conﬁrming, via post mortem gas-
trointestinal content sampling, that the solid content in the stomach
after an overnight fast was negligible (Fig. 3). Therefore, overall this
study protocol conﬁrms that the overnight fasting was suﬃcient to
induce a fasted state. Paracetamol may not be suitable marker of food
induced changes in gastric emptying, which will be discussed further in
a subsequent section.
Suenderhauf et al. (2014) reported a total content of 76 ± 37 g was
retained after an overnight fast in the stomach of Göttingen minipigs. In
the present study in landrace pigs, the overall amount on contents re-
maining in the stomach after the fasting protocol was lower. In parti-
cular, by separating into liquid (33.4 ± 10.7 mL) and solid
(10.1 ± 6.4 g) components, this study conﬁrms near-complete stomach
emptying of solid content was achieved. In the fed state a signiﬁcant
increase in solid (112.9 ± 60.1 g) and liquid (95.1 ± 29.4mL) con-
tent was observed in the stomach. Collectively these studies have ad-
vanced the understanding towards establishing a standardised feeding
and fasting protocol in a pig model for food eﬀect studies, that allows
for physiologically relevant comparisons to humans.
4.3. Paracetamol as a marker for gastric emptying
The present study evaluated the absorption of paracetamol in the
fasted and fed state, as paracetamol has been previously used as a
marker for gastric emptying rate. Pharmacokinetics of paracetamol in
pigs were not signiﬁcantly diﬀerent between pre – and postprandial
conditions.
It has previously been hypothesized that a lack of signiﬁcant
changes between the fasted and the fed pigs after the administration of
paracetamol may reﬂect that a truly fasted state could not be achieved
in pigs due to incomplete stomach emptying of food even after an
overnight fast (Suenderhauf et al., 2014). However, based on the post-
mortem assessment of the gastric content in landrace pigs, near-com-
plete stomach emptying of solid content was conﬁrmed and signiﬁcant
diﬀerences in solid content between the fasted and fed state were
achieved, as discussed above (Section 4.2). While clear diﬀerences in
Fig. 4. (A) Plasma concentration proﬁles after oral
administration of 500mg paracetamol to landrace
pigs, fasted state (●), FDA breakfast (□), pig pellet
feed (▲), (mean ± SEM, n=4), (B) tmax
(median ± range), (C) Mean absorption time
(median ± range), (D) mean deconvolution pro-
ﬁles: fasted state (●), FDA breakfast (□), pig pellet
feed (▲), (mean ± SEM, n=4).
Fig. 5. Food eﬀect illustrated as fold diﬀerence in AUCfed/AUCfasted (0 h – ∞),
data is presented as mean ± SD. In both studies a micronized fenoﬁbrate
formulation was used, the fed state was representative by a FDA style breakfast
of 1000 kcal and 444 kcal in humans and pigs, respectively (Guivarc'h et al.,
2004).
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rate and extent of absorption of fenoﬁbrate were conﬁrmed in pigs, the
lack of diﬀerences in absorption of paracetamol between pre and post
prandial conditions in pigs merits further discussion. As a BCS class I
compound, paracetamol is neither permeability or solubility limited.
Paracetamol, which was co-administered with 50mL water under
fasted and fed condition, is therefore expected to dissolve rapidly in
gastric ﬂuids following ingestion. One plausible explanation for the lack
of a delayed absorption of paracetamol and hence no shift of tmax under
fed conditions may reﬂect a phenomenon similar to the “Magenstrasse”
(or stomach road) for gastric emptying of liquids in humans (Pal et al.,
2007). The Magenstrasse in humans is considered a bypass route of
liquids to travel directly from the fundus and passes through the an-
trum, where the liquid gastric contents are directed directly to the in-
testine, independent of normal gastric contraction patterns. Even under
fed state conditions liquid gastric content can be emptied rapidly into
the intestine (Weitschies and Wilson, 2011). Kelly et al. (2003) con-
ducted a study in humans with radiolabelled paracetamol to assess
gastric emptying in fasted and fed conditions (Kelly et al., 2003). Un-
expectedly the absorption of paracetamol was similar and not statisti-
cally signiﬁcant diﬀerent between the pre- and post-prandial state, or
even faster in the fed state compared to the fasted state for two subjects.
The authors hypothesized that it reﬂected the Magenstrasse phenom-
enon, suggesting that a fast dissolution of paracetamol occurred on top
of the stomach and paracetamol moved along the Magenstrasse with
the liquid content of the stomach directly into the intestine (Weitschies
and Wilson, 2011). Similarly, Grimm et al. (2017), recently used an
MRI study to demonstrate that gastric emptying of water under fed state
clinical trial was as fast as under fasted conditions, which supports the
hypothesis that the Magenstrasse represents a shortcut through the fed
stomach in humans and may explain why a delayed absorption is not
evident in the fed state (Grimm et al., 2017). While the use of radi-
olabelled paracetamol or imaging tools would be required to conﬁrm
conclusively if the Magenstrasse eﬀect is evident in pigs, the lack of a
diﬀerence in paracetamol transit times between fasted and fed state
observed in this study may be indicative of a similar emptying of liquids
in the fasted and fed state pigs.
In contrast, in the case of the low solubility BCS Class II drug fe-
noﬁbrate, the drug will not be soluble in gastric ﬂuid and clearance
from the stomach is likely to be dictated by food induced gastric con-
traction patterns. In summary, while the results support the utility of
co-administrating paracetamol to monitor gastric emptying rate under
fasted conditions, it is not suitable as a marker of gastric emptying
under fed state conditions.
In addition to the limitations outlined above, further limitations of
the in vivo pig model should be considered. While this study has de-
monstrated a positive food eﬀect for micronized fenoﬁbrate, further
studies using a broader range of drugs are warranted before the full
merits of the porcine model can be conﬁrmed. Also, while factors in the
study were adjusted to closely mimic human dosing conditions, there
are inherent diﬀerences between pigs and humans that can lead to in-
accurate scaling predictions. For example, while our data conﬁrmed a
positive food eﬀect at a dose of 4mg/kg in pigs, it is unclear if a similar
eﬀect would also be evident for the entire dose range recommended in
humans (i.e. 1–4mg/kg).
5. Conclusion
The primary objective of this study conﬁrmed that a food eﬀect
protocol in pigs correctly predicted enhanced bioavailability of fenoﬁ-
brate in humans. Post-mortem assessment of the gastrointestinal con-
tent, proved that the overnight fasting protocol was suﬃcient to
achieve a near-complete stomach emptying and established fasting
conditions in landrace pigs. No signiﬁcant diﬀerence in paracetamol
absorption between fasted and fed condition indicated that paracetamol
absorption is not delayed under post prandial conditions. This may
indicate that paracetamol was emptied into the intestine with the co-
administered liquid similar to the well described Magenstrasse phe-
nomenon in humans. Further investigations using more lipophilic
model compounds or monitoring tools like a SmartPill may therefore be
useful to evaluate gastric emptying rate under fasted and fed state
conditions.
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